StreetAlpha.app
Home › Stocks › NVS

Novartis AG (NVS)

Healthcare
$159.16
▼ −0.66%
LAST CLOSE · NOV 17

Novartis develops and sells prescription medicines for heart, immune, nerve and cancer conditions. It last closed at $159.16 on Nov 17, down 0.66% on the day. NVS reports earnings on Wed, Feb 3, 2027. Over the past 90 days StreetAlpha recorded 2 whale options trades in NVS, 50% of them bullish and 50% bearish. In the past 30 days there were 5 dark pool prints totaling $13.5M, the largest $9.1M.

AI Auto Pilots
Is NVS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
$14.0B
+17.1% vs a year ago
Free cash flow
$17.6B
Balance sheet
Cash & equivalents
$11.4B
At Dec 31
Debt
$28.7B
At Dec 31
Shareholder equity
$46.5B
CEOVasant Narasimhan
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $24.0B$24.0BFY2021FY2022: $7.0B$7.0BFY2022FY2023: $14.8B$14.8BFY2023FY2024: $11.9B$11.9BFY2024FY2025: $14.0B$14.0BFY2025

From NVS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 4). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
Feb 3
2027 · Time not announced
Consensus EPS forecast
$2.23
$14.65B revenue est.
Year-ago EPS
$2.03
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated NVS in the past 90 days, not enough for a consensus
Average 12-month target
$136.00
▼ 14.6% downside

Based on 1 analyst who set a price target on NVS in the past 90 days. The average target is $136.00, with a high of $136.00 and a low of $136.00, compared with the last close of $159.16.

$134$144$154$165PAST 17 TRADING DAYS12-MONTH TARGETSHIGH $136AVG $136LOW $136Jul 7LAST CLOSE+12 MO$134$144$154$165PAST 17 DAYSTARGETSHIGH $136AVG $136LOW $136Jul 7LAST CLOSE+12 MO
Highest target$136.00
Average target$136.00
Lowest target$136.00
Latest rating changes
HSBCUpgrade
Sep 10Hold$136
DateFirmActionRatingPrice target
Sep 10HSBCUpgradeHold$136
Loading…

Technical Analysis

NVS · as of the Nov 17 close · updated after every close
Turning up

The stock sits between its 20 and 50 day averages. It is 4% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the swing low (Nov 3) at $158.93, and the nearest resistance the Pivot at $159.19.

Short trendBullish
Long trendNeutral
MomentumNeutral
StretchNormal
VolatilityNormal, 1.9%/day
Key levels
$170.4652 week high+7.1%
$160.00Pivot R1+0.5%
$159.3920 day average+0.1%
$159.30Swing high (Jul 21)+0.1%
$159.19Pivot+0.0%
$159.16Last close
$158.93Swing low (Nov 3)−0.1%
$158.35Pivot S1−0.5%
$152.67200 day average−4.1%
$152.42100 day average−4.2%
$149.5750 day average−6.0%
$123.2452 week low−22.6%
Indicators
RSI (14)55.05Middle of its rangeNeutral
MACD2.90Below its signal lineBearish
Stochastic38.7Middle of its rangeNeutral
ADX (14)25.4Trending up
Williams %R-89.7Oversold below −80, overbought above −20Oversold
CCI (20)-4.2Oversold below −100, overbought above 100Neutral
Rate of change−0.1%Change over 10 sessionsBearish
ATR (14)$3.02Typical daily range, 1.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for NVS

What happened before

See how NVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NVS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Sep 2 – Oct 29
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
5
Notional
$13.5M
Largest print
$9.1M
Loading…

NVS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼555 buying vs 754 selling
  • ▼Shares held by funds -2.0%
  • ▼Funds holding -71
  • ●Superinvestors: 2 added, 2 cut
  • ▲Put/call 4.18 to 2.95
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding1,5551,626−4.4%
In funds' top 1010100.0%
Held by funds–––
New / increased92 / 463109 / 519−11.6%
Reduced / sold out615 / 139558 / 90+16.4%
Put/call ratio2.954.18−29.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NVS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NVS is in one of them and how their past NVS trades turned out.

NVS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NVS in an article yet. Here's the latest on the wider market.

NVS Congress Trades

All congress trades →
Trades, 12 months
7
Buys
3
43%
Sells
4
57%
People
4
Last filed Sep 28
Who traded NVS · since 2016
Latest 5 filings of 72
$15K – $50KTraded Aug 27, 2026Filed Sep 28, 2026
$1K – $15KTraded Mar 31, 2026Filed Jul 21, 2026
$15K – $50KTraded Mar 30, 2026Filed Jul 21, 2026
$1K – $15KTraded Jan 30, 2026Filed Apr 10, 2026
$1K – $15KTraded Oct 31, 2025Filed Nov 21, 2025
PersonTypeAmountTradedFiledDelay
Kevin HernR · OKSell$15K – $50KAug 27, 2026Sep 28, 202632 d
Alan ArmstrongHouseBuy$1K – $15KMar 31, 2026Jul 21, 2026112 d
Alan ArmstrongHouseBuy$15K – $50KMar 30, 2026Jul 21, 2026113 d
Arjun ModyExecutive branchSell$1K – $15KJan 30, 2026Apr 10, 202670 d
Lisa McClainR · MISell$1K – $15KOct 31, 2025Nov 21, 202521 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Novartis AG

Novartis is a pharmaceutical company based in Basel, Switzerland. It develops and sells medicines in four main therapeutic areas: cardiovascular, renal and metabolic conditions, immunology, neuroscience, and oncology. Its main products include Entresto for heart failure, Cosentyx for psoriasis and Kisqali for breast cancer. Its customers include patients and healthcare systems, with the US, China, Germany and Japan as priority markets.

Headquarters
Basel, Switzerland
Founded
1996